Metsera (MTSR) Competitors $36.29 +0.63 (+1.77%) As of 09/4/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock MTSR vs. VTRS, ASND, RDY, QGEN, BBIO, MRNA, ELAN, VRNA, ROIV, and RVMDShould you be buying Metsera stock or one of its competitors? The main competitors of Metsera include Viatris (VTRS), Ascendis Pharma A/S (ASND), Dr. Reddy's Laboratories (RDY), Qiagen (QGEN), BridgeBio Pharma (BBIO), Moderna (MRNA), Elanco Animal Health (ELAN), Verona Pharma PLC American Depositary Share (VRNA), Roivant Sciences (ROIV), and Revolution Medicines (RVMD). These companies are all part of the "pharmaceutical products" industry. Metsera vs. Its Competitors Viatris Ascendis Pharma A/S Dr. Reddy's Laboratories Qiagen BridgeBio Pharma Moderna Elanco Animal Health Verona Pharma PLC American Depositary Share Roivant Sciences Revolution Medicines Metsera (NASDAQ:MTSR) and Viatris (NASDAQ:VTRS) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, risk, profitability, institutional ownership, media sentiment, valuation, earnings and analyst recommendations. Do insiders & institutionals believe in MTSR or VTRS? 79.9% of Viatris shares are owned by institutional investors. 0.1% of Viatris shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Do analysts recommend MTSR or VTRS? Metsera presently has a consensus price target of $59.00, indicating a potential upside of 62.58%. Viatris has a consensus price target of $10.40, indicating a potential upside of 0.68%. Given Metsera's stronger consensus rating and higher possible upside, equities research analysts plainly believe Metsera is more favorable than Viatris.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Metsera 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00Viatris 2 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 1.80 Does the media favor MTSR or VTRS? In the previous week, Metsera had 11 more articles in the media than Viatris. MarketBeat recorded 14 mentions for Metsera and 3 mentions for Viatris. Metsera's average media sentiment score of 1.37 beat Viatris' score of -0.01 indicating that Metsera is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Metsera 10 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Viatris 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Is MTSR or VTRS more profitable? Metsera has a net margin of 0.00% compared to Viatris' net margin of -24.57%. Viatris' return on equity of 16.54% beat Metsera's return on equity.Company Net Margins Return on Equity Return on Assets MetseraN/A N/A N/A Viatris -24.57%16.54%7.06% Which has better earnings & valuation, MTSR or VTRS? Metsera has higher earnings, but lower revenue than Viatris. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMetseraN/AN/A-$209.13MN/AN/AViatris$14.74B0.82-$634.20M-$2.90-3.56 SummaryMetsera beats Viatris on 7 of the 12 factors compared between the two stocks. Get Metsera News Delivered to You Automatically Sign up to receive the latest news and ratings for MTSR and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MTSR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MTSR vs. The Competition Export to ExcelMetricMetseraMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.75B$3.13B$5.76B$9.85BDividend YieldN/A2.28%6.67%4.51%P/E RatioN/A20.8975.9926.43Price / SalesN/A458.96546.94119.09Price / CashN/A44.5237.0558.92Price / Book-14.759.9310.916.06Net Income-$209.13M-$53.38M$3.29B$266.28M7 Day Performance2.83%0.63%0.18%-0.32%1 Month Performance8.82%6.31%6.26%3.44%1 Year PerformanceN/A11.63%51.54%23.11% Metsera Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MTSRMetseraN/A$36.29+1.8%$59.00+62.6%N/A$3.75BN/A0.0081News CoverageAnalyst ForecastVTRSViatris1.782 of 5 stars$10.55+1.3%$10.40-1.4%-12.3%$12.14B$14.74B-3.6437,000ASNDAscendis Pharma A/S3.4483 of 5 stars$194.27+0.2%$243.36+25.3%+65.8%$11.87B$393.54M-37.65640News CoveragePositive NewsAnalyst ForecastRDYDr. Reddy's Laboratories2.788 of 5 stars$14.20-0.1%$16.95+19.4%-13.4%$11.86B$334.26B21.5124,800Positive NewsQGENQiagen4.276 of 5 stars$46.53+0.9%$49.69+6.8%+9.5%$10.26B$1.98B27.496,030Positive NewsBBIOBridgeBio Pharma4.1797 of 5 stars$51.76-1.5%$62.18+20.1%+69.0%$10.05B$221.90M-12.66400Positive NewsAnalyst ForecastMRNAModerna4.5595 of 5 stars$24.09-1.6%$42.88+78.0%-66.5%$9.52B$3.24B-3.203,900ELANElanco Animal Health3.0977 of 5 stars$18.38-0.4%$17.33-5.7%+16.3%$9.17B$4.44B21.379,800Analyst RevisionHigh Trading VolumeVRNAVerona Pharma PLC American Depositary Share2.6177 of 5 stars$105.91+0.0%$109.00+2.9%+286.0%$9.16B$42.28M-106.9830News CoveragePositive NewsROIVRoivant Sciences3.1307 of 5 stars$11.93-0.1%$16.50+38.3%+7.0%$8.15B$23.23M-17.04860News CoveragePositive NewsAnalyst ForecastRVMDRevolution Medicines4.5639 of 5 stars$37.97-0.9%$69.92+84.2%-8.2%$7.16B$11.58M-8.44250Positive NewsInsider Trade Related Companies and Tools Related Companies VTRS Alternatives ASND Alternatives RDY Alternatives QGEN Alternatives BBIO Alternatives MRNA Alternatives ELAN Alternatives VRNA Alternatives ROIV Alternatives RVMD Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MTSR) was last updated on 9/5/2025 by MarketBeat.com Staff From Our Partners“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredHow “Trump’s New Dollar” Could Impact Your WealthPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredWhat's the Best Way to Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredOne tiny company just cracked Google’s $19B problemFor decades, this “AI metal” was trapped in labs, too slow and expensive to ever reach mass production. The...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Metsera Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Metsera With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free MTSR Stock Alerts